Kyriakos A. Kirou, MD, FACR
Dr. Kyriakos A. Kirou, Assistant Attending Physician at Hospital for Special Surgery, is a physician-scientist in the field of academic rheumatology. He has a special interest in the research and treatment of systemic autoimmune rheumatic diseases, such as systemic lupus erythematosus.
Appointments
Assistant Professor of Medicine, Weill Medical College of Cornell University
Assistant Attending Physician, Hospital for Special Surgery
Specialty
Rheumatology
Certification
Rheumatology
Internal Medicine
State Licensure
New York
Education
MD, Aristotle University of Thessaloniki, Greece
Residency
New York Hospital of Queens, Flushing, New York, US
Fellowship
Hospital for Special Surgery, US
Kyriakos A. Kirou, MD, FACR is the author of the following articles on HSS.edu:
For Professionals
Special Expertise
Systemic lupus erythematosus
Systemic sclerosis
Rheumatoid arthritis
Psoriatic arthritis
Awards
Mentored Clinical Scientist Development Award (KO8), 2003
Foundation global Arthritis Research Network Travel Grant, 2002
Merck 2000 Rheumatology Young Investigator, 2000
Extended Fellowship Grant Award (3 years), The SLE Foundation Inc., 1999
Fellowship Grant Award, Arthritis Foundation, New York Chapter, 1998
Affiliations
Basic Research in autoimmune diseases
Rheumatology Practice
Teaching
Peer-review in immunology research
Selected Publications
Vakkalanka RK, Woo C, Kirou KA, Koshy M, Berger D, Crow MK. The soluble form of CD40 ligand is present in systemic lupus erythematosus sera and correlates with disease activity. Arthritis Rheum 1999; 42:871-81.
Bateman HE, Kirou KA, Paget S A., Crow M K., Yee AMF. Case report: remission of juvenile rheumatoid arthritis (JRA) after infection with parvovirus B19. J Rheumatol 1999; 26:2482-84.
Kirou KA, Vakkalanka RK, Butler MJ, Crow MK. Induction of Fas ligand-mediated apoptosis by interferon-alpha. Clin Immunol 2000; 95:218-26.
Kirou KA, Bateman HE, Bansal M, Schneider R, Crow MK, Fantini GA, Paget SA. Sarcoidosis presenting with large vessel vasculitis and osteosclerosis-related bone and joint pain. Clin Exp Rheumatol 2000; 18:401-03.
Chernysheva A, Kirou KA, Crow MK. T cell proliferation induced by autologous non-T cells is a response to apoptotic cells processed by dendritic cells. J Immunol 2002; 169:1241-50.
For more publications, please see the
PubMed listing.
Clinical Trials
- A Phase 1b Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation study with an open-label extension to evaluate the safety and tolerability of multiple IV doses of Medi-545, a fully Human Anti-interferon-alpha Monoclonal Antibody,
- A Phase I, Randomized, Double-blind, Placebo-controlled, Escalating Single- and Multiple-dose Study of the Safety, Tolerability, and Pharmakokinetics of RhuMab IFN alpha in Adults with Systemic Lupus Erythematosus
- The Systemic Lupus Erythematosus (SLE) Activity Gene Expression (SAGE) Study
- Gleevec in the Treatment of Systemic Sclerosis
- A Sequential Adaptive Phase II/III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept Versus Placebo on a Background of Mycophenolate Mofetil and Glucocorticosteroids
- Scleroderma Cyclophosphamide or Transplantation (SCOT) Study
- Scleroderma Registry
- A Phase I, Randomized, Double-Blind, Placebo Controlled, Dose-Escalation Study To Evaluate Safety And Tolerability Of A Single IV Dose Of MEDI-545, A Fully Human Monoclonal Antibody Directed Against Interferon Alpha Subtypes
- Rituximab Therapy For The Induction Of Remission And Tolerance In ANCA-Associated Vasculitis
